Evaluating TBK1 as a therapeutic target in cancers with activated IRF3

Molecular Cancer Research

Volumn 12, Issue 7, 2014, Pages 1055-1066

  Muvaffak, Asli ^a   Pan, Qi ^a   Yan, Haiyan ^a   Fernandez, Rafael ^b   Lim, Jongwon ^b   Dolinski, Brian ^b   Nguyen, Thi T ^b   Strack, Peter ^b   Wu, Stephen ^a   Chung, Rossana ^a   Zhang, Weiqun ^a   Hulton, Chris ^a   Ripley, Steven ^a   Hirsch, Heather ^b   Nagashima, Kumiko ^b   Wong, Kwok Kin ^a   Jánne, Pasi A ^a   Seidel Dugan, Cynthia ^b   Zawel, Leigh ^b   Kirschmeier, Paul T ^a   Middleton, Richard E ^a   Morris, Erick J ^b   Wang, Yan ^b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE; INTERFERON REGULATORY FACTOR 3; K RAS PROTEIN; SHORT HAIRPIN RNA; TANK BINDING KINASE 1; UNCLASSIFIED DRUG; IRF3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TBK1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; GENE SILENCING; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; NEOPLASM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-3; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84904258149     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0642     Document Type: Article

References (40)

1. Shen RR, Hahn WC. Emerging roles for the noncanonical IKKs in cancer. Oncogene 2011;30:631- 41.
2. KimJY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 2013;110:12414-9.
3. Tu D, Zhu Z, Zhou AY, Yun CH, Lee KE, Toms AV, et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 2013;3:747-58.
4. Kim JY, Beg AA, Haura EB. Noncanonical IKKs, IKKε and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer. Expert Opin Ther Targets 2013;17:1109-12.
5. Vangamudi B, Ayres AE, Burke JP, Waterson AG, Rossanese OW, Fesik SW. Evaluation of TBK1 as a novel cancer target in the KRAS pathway [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL: AACR; 2012. Abstract nr 1813.
6. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic Kras-driven cancers require TBK1. Nature 2009;462:108-12.
7. Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G, et al. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 2011;108:6474-9.
8. Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011;41:458-470.
9. Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006;127:157-70. (Pubitemid 44472624)
10. Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 2009;284:14136-46.
11. Larabi A, Devos JM, Ng SL, Nanao MH, Round A, Maniatis T, et al. Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep 2013;3:734-46.
12. The Human Protein Atlas project (funded by the Knut & Alice Wallenberg foundation), http://www.proteinatlas.org/search/tbk1.
13. Bonnard M, Mirtsos C, Suzuki S, Graham K, Huang J, Ng M, et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired Nf-kappaB-dependent gene transcription. EMBO J 2000;19: 4976-85.
14. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999;284:321-5.
15. Clark K, Takeuchi O, Akira S, Cohen P. The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signaling. Proc Natl Acad Sci U S A 2011;108: 17093-8.
16. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-6. (Pubitemid 36592443)
17. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003;300:1148-51. (Pubitemid 36583100)
18. Black KE, Collins SL, Hagan RS, Hamblin MJ, Chan-Li Y, Hallowell RW, Powell JD, Horton MR. Hyaluronan fragments induce IFNb via a novel TLR4-TRIF-TBK1-IRF3-dependent pathway. J Inflamm 2013; 10:23.
19. Goncalves A, Bürckstümmer T, Dixit E, Scheicher R, Górna MW,Karayel E, et al. Functional dissection of the TBK1 molecular network. PLoS ONE 2011;6:e23971.
20. Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK, TBK1, a novel IKK related kinase. EMBO J 1999;18:6694 -704.
21. Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, et al. IKK-i, a novel lipopolysaccharide-inducible kinase that is related that is realted to IkappaB kinases. Int Immunol 1999;11:1357-62. (Pubitemid 29355675)
22. Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP, et al. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem Sci 2008;33:171-80.
23. Takahasi K, Suzuki NN, Horiuchi M, Mori M, Suhara W, Okabe Y, et al. X-ray crystal structure of IRF-3 and its functional implications. Nat Struct Biol 2003;10:922-7. (Pubitemid 37386101)
24. Mori M, Yoneyama M, Ito T, Takahashi K, Inagaki F, Fujita T. Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. J Biol Chem 2004;279:9698-702. (Pubitemid 38372567)
25. Servant MJ, Grandvaux N, tenOever BR, Duguay D, Lin R, Hiscott J. Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. J Biol Chem 2003;278:9441-7. (Pubitemid 36800435)
26. Ogasawara N, Sasaki M, Itoh Y, Tokudome K, Kondo Y, Ito Y, et al. Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFNα/β reduction. J Clin Biochem Nutr 2011; 48:154-60.
27. Marion JD, Roberts CF, Call RJ, Forbes JL, Nelson KT, Bell JE, et al. Mechanism of endogenous regulation of the type I interferon response by suppressor of IkB kinase {epsilon} (SIKE), a novel substrate of TANK-binding kinase 1 (TBK1). J Biol Chem 2013;288:18612-23.
28. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008;455:674-8.
29. Chen H, Sun H, You F, Sun W, Zhou X, Chen L, et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 2011; 147:436-46.
30. Bowie A. The STING in the tail for cytosolic DNA-dependent activation of IRF3. Sci Signal 2012;5:pe9.
31. Ma X, Helgason E, Phung QT, Quan CL, Iyer RS, Lee MW, et al. Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation. Proc Natl Acad Sci U S A 2012;109:9378-83.
32. Holcomb R, Suzuki K, Halter RJ, Sebahar PR, Mcleod DA, Shenderovich MD, et al. Amino-Pyrimidine Compounds as Inhibitors of TBK1 and/or IKK epsilon. 2011 (patent WO/2011/046970).
33. McIver EG, Bryans J, Birchall K, Chugh J, Drake T, Lewis SJ, et al. Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases. Bioorg Med Chem Lett 2012;22:7169-73.
34. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches idebtify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-79. (Pubitemid 46891036)
35. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009;34:461-72.
36. Shen RR, Zhou AY, Kim E, Lim E, Habelhah H, Hahn WC. IkB kinase e phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol 2012;32:4756-68.
37. Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population ofRAS pathway activated tumors.BMCMed Genomics 2010;3:26.
38. McIver EG, Bryans JS, Smiljanic E, Lewis SJ, Hough J, Drake T. Preparation of pyrimidine derivatives capable of inhibiting one or more kinases. 2009 (patent WO 2009122180).
39. McIver EG, Hough J. Preparation of pyrrolopyrimidines as kinase inhibitors. 2010 (patent WO 2010100431).
40. Li J, HuangJ, Jeong JH,Park SJ,WeiR,PengJ, et al. Selective TBK1/IKKi dual inhibitors with anticancer potency. Int J Cancer 2013;134:1972-80.